Foghorn therapeutics to participate at the evercore isi healthconx conference

Cambridge, mass., nov. 22, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that adrian gottschalk, president and chief executive officer, will participate in the evercore isi healthconx conference which will be held virtually on november 30, 2022. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people with a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking